TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05780658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compass Course
Description: An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
Study: NCT05518539

Intervention type: DEVICE
Intervention: The Clareon™ PanOptix™ Trifocal (toric and non-toric models)
Description: Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
Study: NCT05731895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (iclepertin)
Description: BI 425809 (iclepertin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (iclepertin)
Description: BI 425809 (iclepertin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (iclepertin)
Description: BI 425809 (iclepertin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (iclepertin)
Description: BI 425809 (iclepertin)
Study: NCT04964531

Intervention type: OTHER
Intervention: speckle tracking echocardiography
Description: before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views

Intervention type: OTHER
Intervention: speckle tracking echocardiography
Description: before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
Study: NCT05413616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITFOOD lifestyle intervention
Description: Lifestyle intervention with a nutritional and exercise component.
Study: NCT05245318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical care
Description: The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blended physiotherapy program
Description: The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
Study: NCT05599061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Description: Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Description: OPTIMAL MEDICAL TREATMENT (OMT)
Study: NCT06118606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-manager led multidisciplinary follow-up after intensive care
Description: Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
Study: NCT05710692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102 1 mg/kg every 2 weeks
Description: PRX-102 1 mg/kg every 2 weeks
Study: NCT06180499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-reg depleted DLI
Description: Treg depleted Donor Lymphocytes Infusion
Study: NCT06089733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A ABSK201 and Itraconazole
Description: Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A ABSK201 and Rifampicin
Description: Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
Study: NCT04315727

Intervention type: GENETIC
Group type: OTHER
Intervention: WGS Diagnostic Blood take for genetic diagnostic.
Description: Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).

Intervention type: GENETIC
Group type: OTHER
Intervention: Hair collection
Description: Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
Study: NCT05684692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: A chimeric immunoglobulin G mAb, via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab-Aooe
Description: Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab Matching Placebo
Description: Dextrose 5% in water, via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab-Aooe Matching Placebo
Description: 0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
Study: NCT06698978

Intervention type: OTHER
Group type: OTHER
Intervention: Simplified protocol (PS)/Conventional protocol (PC)
Description: Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional protocol (PC)/Simplified protocol (PS)
Description: Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS)in period 2 (3 months).
Study: NCT06699901

Intervention type: OTHER
Intervention: Massive Transfusion Group
Description: This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.

Intervention type: OTHER
Intervention: Control Group
Description: This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
Study: NCT05928845

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle thickness measurement
Description: Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
Study: NCT06518486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot-ankle exercise
Description: Foot-ankle exercise group will receive usual care provide by public health center and intervention through health education, leaflets, and videos about foot-ankle exercise. At the first meeting, participants will be taught how to do foot exercises and practice them in front of the instructor. Afterwards, participants will practice foot exercises independently without supervision for 12 weeks. One foot exercise session takes 10-15 minutes, while the physical activity target is for participants to fulfil a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do foot exercises for 2-3 sessions every day. The minimum duration of each session is 10 minutes, and two consecutive days without foot exercise are not allowed. Participants are asked to document all foot exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for a minimum of 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Participants in the walking exercise group will receive usual care provide by public health center and intervention through health education and leaflets about walking exercise. Participants will practice walking exercises independently without supervision for 12 weeks. Participants walked at the same speed as they did every day. The physical activity target to be achieved is for participants to be able to engage in a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do walking exercises with a minimum duration of 10 minutes for each session. Two consecutive days without walking exercise are not allowed, and a minimum of 150 minutes/week is allowed. Participants are asked to document all walking exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for a minimum of 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care and health education
Description: Participants in the control group will receive the usual care provided by the community health center and intervention in the form of health education about DM in general.
Study: NCT04566250

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Opioid Prescription and Infographic
Description: The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Non-Opioid Prescription and Infographic
Description: The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control.
Study: NCT05220501

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Micro-US Targeted Biopsy
Description: All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Micro-US Targeted Biopsy
Description: All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
Study: NCT04838639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NO-13065
Description: Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects per cohort will take a matched placebo.
Study: NCT05620485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted CDC excision and hepaticojejunostomy
Description: After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
Study: NCT05710692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102 2 mg/kg every 4 weeks
Description: PRX-102 2 mg/kg every 4 weeks
Study: NCT04305951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive acupuncture therapy (CAT)
Description: CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive acupuncture therapy (CAT)
Description: CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes.
Study: NCT05482594

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.

Intervention type: DIAGNOSTIC_TEST
Intervention: Videocapillaroscopy
Description: Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Videocapillaroscopy
Description: Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
Study: NCT05937490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enantone
Description: administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2 MG (milligram)
Description: Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enantone
Description: COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enantone
Description: COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).

Intervention type: DRUG
Group type: OTHER
Intervention: long GnRH agonist or flexible GnRH antagonist protocol.
Description: During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
Study: NCT05053074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow (NHF)
Description: Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow (NHF)
Description: Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
Study: NCT05746689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
Study: NCT05432895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic splint
Description: Device treats plantar fasciitis and replacing boot immobilization which is quite benign
Study: NCT04305951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comfy Acupressure for the Elderly (CAE)
Description: CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comfy Acupressure for the Elderly (CAE)
Description: CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM.
Study: NCT06005532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab injection 40 mg / 0.8 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Adalimumab injection 40 mg / 0.4 ml